Black Rock Inc. Curis Inc Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.57 - $0.99 $123,247 - $214,061	-216,224 Reduced 15.59%	1,171,027 $971,000
Q1 2023 May 12, 2023	SELL	$0.51 - $0.78 $80,004 - $122,359	-156,871 Reduced 10.16%	1,387,251 $832,000
Q4 2022 Feb 13, 2023	SELL	$0.47 - $17.22 $437,659 - $16 Million	-931,191 Reduced 37.62%	1,544,122 $849,000
Q3 2022 Nov 14, 2022	BUY	$0.74 - $15.01 $85,489 - $1.73 Million	115,526 Added 4.9%	2,475,313 $1.73 Million
Q2 2022 Aug 12, 2022	SELL	$0.71 - $2.43 $3 Million - $10.3 Million	-4,227,594 Reduced 64.18%	2,359,787 $2.32 Million
Q1 2022 May 12, 2022	BUY	$2.31 - $5.13 $707,645 - $1.57 Million	306,340 Added 4.88%	6,587,381 $15.7 Million
Q4 2021 Feb 10, 2022	BUY	$4.45 - $8.09 $2.54 Million - $4.61 Million	569,846 Added 9.98%	6,281,041 $29.9 Million
Q3 2021 Nov 09, 2021	BUY	$6.94 - $8.85 $9,056 - $11,549	1,305 Added 0.02%	5,711,195 $44.7 Million
Q2 2021 Aug 11, 2021	BUY	$7.45 - $16.27 $42.5 Million - $92.9 Million	5,709,890 New	5,709,890 $46.1 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.